SOURCE: PuriCore Plc

February 05, 2007 08:00 ET

PuriCore Plc announces Re Agreement

Pennsylvania -- (MARKET WIRE) -- February 5, 2007 --


5 February 2007



  PuriCore Signs Exclusive UK Distribution Agreement with Minntech Corporation

                   to Expand its Sterilox Endoscopy Portfolio



PuriCore (LSE: PURI), the life sciences company focused on the development and
commercialisation of its novel, safe antimicrobial technology, today announces
that its Sterilox Endoscopy division has signed an exclusive distribution
agreement with Minntech Corporation ("Minntech"), one of the world's leading
manufacturers of automated endoscope reprocessors ("AER"), and a subsidiary of
Cantel Medical Corp (NYSE: CMN).



This partnership significantly enhances PuriCore's product portfolio combining
its award winning Sterilox Solution with Minntech's MDS reprocessor systems, the
latest innovation in asynchronous AER technology.



Under the terms of the agreement, PuriCore is responsible for distributing and
servicing Minntech's endoscopy reprocessing portfolio, including its new MDS
AER, to UK hospitals.  Minntech's UK sales and technical support team will
become employees of PuriCore's Sterilox Endoscopy division, and Sterilox
Endoscopy will now service Minntech's installed base of approximately 125 AERs
in UK hospitals, bringing PuriCore's total AER network to circa 600,
representing an estimated 33% of the installed AER market.  Additionally,
Sterilox Endoscopy now has the opportunity to expand its market penetration
strategy into the asynchronous AER segment, which represents around 27% of the
total UK AER market.  The agreement is effective immediately.



Greg Bosch, Chief Executive of PuriCore, said:



"Our partnership with Minntech reflects the next step in the evolution of our
Sterilox Endoscopy business.  Together, the combined strength of our products,
teams, and installed base will enable us to respond better to market demands in
the UK.  This combination further strengthens Sterilox Endoscopy's position as
the UK's leading provider of endoscopy reprocessing systems."



Roy K. Malkin, President and CEO of Minntech Corporation, said:



"We are very pleased with the past performance of our Minntech UK team, and are
extremely  excited about our new partnership with Sterilox Endoscopy that will
allow us to even better serve our long term customers in the UK. I am confident
that Sterilox Endoscopy is well positioned to market and service our products in
the UK, and in the not too distant future, we look forward to launching a
dedicated Minntech MDS reprocessor for use with the Sterilox Solution that
promises to provide the absolute best alternative for our mutual endoscopy
customers.



"We will be working closely with the Sterilox Endoscopy team to ensure a
seamless transition of customer support."



Contacts:


PuriCore plc                                           +1 (484) 321-2700
Greg Bosch, Chief Executive Officer
Keith A. Goldan, Chief Financial Officer

Financial Dynamics                                     Tel: +44 (0) 20 7831 3113
Ben Brewerton
John Gilbert



Notes to Editors: Sterilox Endoscopy is a division of PuriCore.



About PuriCore



PuriCore (LSE: PURI) is a life sciences company focused on the development and
commercialisation of its proprietary technology that mimics the production by
the human body of its natural anti-microbial, hypochlorous acid. Hypochlorous
acid is highly effective at killing pathogens such as bacteria, viruses and
fungi and yet is safe and environmentally friendly.  PuriCore's solutions have
applications in a wide range of markets where it is important to control
microbial contamination.  These markets include medical device disinfection,
food safety, dental equipment decontamination, environmental remediation,
hospitality, water safety, wound management and other applications intended to
limit the spread of infectious disease, including major global disease threats
such as Tuberculosis, MRSA, Influenza, E.coli, Norovirus, HIV, polio, Hepatitis
A, H.pylori and Legionella.



PuriCore markets a portfolio of branded systems which produce hypochlorous acid
solutions on-site at a customer's location from water, electricity and common
salt.  These solutions are generated at a range of concentrations and at a
nearly neutral pH range similar to the human body. They are effective as soaks,
sprays, mists and in other forms.



PuriCore is headquartered in Malvern, Pennsylvania with offices in Stafford, UK.



To receive additional information on PuriCore or its Sterilox Endoscopy
division, please visit our web site at www.puricore.com, which does not form
part of this press release.



About Minntech



Minntech is one of the world's leading manufacturers of endoscopy AERs with over
62% of the US GI market and a strong European distribution network.  The company
was founded in 1974, and since 2001 has been a part of Cantel Medical Corp., a
leading provider of infection prevention and control products in the healthcare
market. Cantel's products include specialized medical device reprocessing
systems for renal dialysis and endoscopy, dialysate concentrates and other
dialysis supplies, disposable infection control products primarily for the
dental industry, water purification equipment, sterilants, disinfectants and
cleaners, hollow fiber membrane filtration and separation products for medical
and non-medical applications, and specialty packaging for infectious and
biological specimens. Cantel also provides technical maintenance for its
products and offers compliance training services for the transport of infectious
and biological specimens.





                      This information is provided by RNS
            The company news service from the London Stock Exchange